2-acetoxy-1,4-dioxane | 1743-23-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 2-acetoxy-1,4-dioxane
• 英文别名: Dioxane acetate；1,4-dioxan-2-yl acetate
• CAS: 1743-23-3
• 化学式: C₆H₁₀O₄
• 分子量: 146.143
• InChiKey: YSBHDZULGNBTHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-acetoxy-1,4-dioxane 反应 0.42h， 以61%的产率得到1,4-二氧杂-2-己烯
  参考文献：
  名称：

  1,4-DIOXENE

  摘要：

  DOI：

  10.15227/orgsyn.082.0099
• 作为产物：
  描述：

  1,4-二氧六环 、 lead(IV) tetraacetate 反应 1.5h， 以73%的产率得到2-acetoxy-1,4-dioxane
  参考文献：
  名称：

  1,4-DIOXENE

  摘要：

  DOI：

  10.15227/orgsyn.082.0099

文献信息

• Microwave-Enhanced Coupling of Carboxylic Acids with Liquid Ketones and Cyclic Ethers Using Tetrabutylammonium Iodide/<i>t</i>-Butyl Hydroperoxide
  作者：Pablo Macías-Benítez、F. Javier Moreno-Dorado、Francisco M. Guerra

  DOI：10.1021/acs.joc.0c00519

  日期：2020.5.1

  The oxidative coupling of carboxylic acids with liquid ketones and cyclic ethers has been accomplished in minutes using t-butyl hydroperoxide in the presence of tetrabutylammonium iodide under microwave irradiation in the absence of a solvent. In addition to drastically shortening the reaction times, the use of microwaves resulted, in general, in yields equal to or higher than those obtained by conventional

  在叔丁基碘化铵存在下，在无溶剂的情况下，在微波辐射下，使用叔丁基氢过氧化物在几分钟之内完成了羧酸与液态酮和环醚的氧化偶联。除了大大缩短反应时间之外，使用微波通常还产生等于或高于通过常规加热获得的产率。
• Anti-infective agents
  申请人：——

  公开号：US20040162285A1

  公开（公告）日：2004-08-19

  Compounds having the formula 1 are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

  具有公式1的化合物是丙型肝炎病毒（HCV）聚合酶抑制剂。还公开了一种用于抑制丙型肝炎病毒（HCV）聚合酶的组成和方法，用于制造这些化合物的过程，以及在这些过程中使用的合成中间体。
• [EN] BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION<br/>[FR] COMPOSÉS 5,6-HÉTÉROAROMATIQUES CONTENANT DE LA BENZYLAMINE UTILES CONTRE UNE INFECTION MYCOBACTÉRIENNE
  申请人：SHIONOGI & CO

  公开号：WO2021050708A1

  公开（公告）日：2021-03-18

  A compound represented by formula (I):, or its pharmaceutically acceptable salt, wherein a group represented by formula: (II) is a group represented by formula: (III) or (IV); R1 is each independently halogen, hydroxy, cyano or the like; m is 0, 1, 2, 3 or 4; R2 is a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like; R3a,R3b,R3c andR3d are each independently hydrogen atom, halogen or the like, with the proviso that R3a,R3b,R3c andR3d are not simultaneously hydrogen atom; ring C is represented as follows: (V), (VI), (VII), (VIII), (IX) or (X). X is CH or N; Y is CH or N; R4 is each independently halogen, hydroxy, cyano or the like; p is 0 or 1; q is 0, 1, 2, 3 or 4; R5 is CR5C or N; R6 is CR6C or N; R7 is CR7C or N; R8 is CR8C or N; R9 is CR9C or N; with the proviso that R5,R6,R7,R8 andR9 are not simultaneously N; R5C,R6C,R7C,R8C andR9C are each independently hydrogen atom or the like.

  公式（I）表示的化合物，或其药用可接受的盐，其中由公式（II）表示的基团为由公式（III）或（IV）表示的基团；R1分别为卤素、羟基、氰基或类似物；m为0、1、2、3或4；R2为氢原子、卤素、氰基、取代或未取代的烷基或类似物；R3a、R3b、R3c和R3d分别为氢原子、卤素或类似物，但R3a、R3b、R3c和R3d不能同时为氢原子；环C表示如下：（V）、（VI）、（VII）、（VIII）、（IX）或（X）。X为CH或N；Y为CH或N；R4分别为卤素、羟基、氰基或类似物；p为0或1；q为0、1、2、3或4；R5为CR5C或N；R6为CR6C或N；R7为CR7C或N；R8为CR8C或N；R9为CR9C或N；但R5、R6、R7、R8和R9不能同时为N；R5C、R6C、R7C、R8C和R9C分别为氢原子或类似物。
• Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives
  申请人：Li Song

  公开号：US20120122914A1

  公开（公告）日：2012-05-17

  The present invention relates to a sustained-release composition containing 2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof as an active ingredient, preparation thereof and the compound. The composition is suitable for oral administration by one time per day, and achieves the peak plasma concentration at 1.0 to 3 hours after oral administration. The composition is suitable for manufacturing a medicament for treatment of cognitive dysfunction syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, or senile dementia.

  本发明涉及一种缓释组合物，其包含2,3,4,5-四氢-2,8-二甲基-5-[2-(6-甲基-3-吡啶基)乙基]-1H-吡啶并[4,3-b]吲哚或其药学上可接受的盐作为活性成分，以及其制备方法和该化合物。该组合物适用于每天一次口服，口服后1.0至3小时达到峰值血浆浓度。该组合物适用于制造治疗认知功能障碍综合征、阿尔茨海默病、帕金森病、亨廷顿病或老年性痴呆的药物。
• Physiologically active substances of plant, process for the preparation thereof, and utilities thereof
  申请人：RESEARCH DEVELOPMENT CORPORATION OF JAPAN

  公开号：EP0576116A1

  公开（公告）日：1993-12-29

  A compound represented by the formula (I) wherein R¹, R², R³, R⁴, and R⁵ each independently represents hydrogen, acetyl or benzyl, R⁶ represents hydrogen, hydroxyl, acetoxy, or benzyloxy, R⁷ represents hydrogen, or R⁶ and R⁷ together represent a direct bond, and R⁸ represents carboxyl, methoxycarbonyl, hydroxymethyl, or acetoxymethyl; or a salt thereof. The compound is useful for plant culture, growth inhibition of moyashi roots, and growth promotion of moyashi hypocotyls.

  由式 (I) 代表的化合物 其中 R¹、R²、R³、R⁴ 和 R⁵ 各自独立地代表氢、乙酰基或苄基，R⁶ 代表氢、羟基、乙酰氧基或苄氧基，R⁷ 代表氢，或 R⁶ 和 R⁷ 共同代表直接键，R⁸ 代表羧基、甲氧羰基、羟甲基或乙酰氧甲基；或其盐。该化合物可用于植物培养、抑制毛豆根的生长和促进毛豆下胚轴的生长。